Dashboard
Manage Tickers

ARQTArcutis Biotherapeutics, Inc.

Nasdaq arcutis.com


$ 10.67 $ -0.10 (-0.93 %)    

Tuesday, 16-Jul-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 496.22 $ 0.19 (0.04 %)
DIA $ 409.69 $ 7.30 (1.81 %)
SPY $ 564.93 $ 3.33 (0.59 %)
TLT $ 94.14 $ 1.31 (1.41 %)
GLD $ 228.28 $ 4.46 (1.99 %)
$ 10.67
$ 11.14
$ 10.64 x 157
$ 0.00 x 0
$ 10.53 - $ 11.17
$ 1.76 - $ 13.17
2,001,469
na
1.18B
$ 0.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-22-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-19-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-approves-expanded-use-of-arcutis-biotherapeutics-eczema-drug-for-patients-as-young-as-6-years
FDA Approves Expanded Use Of Arcutis Bioth...
07/10/2024 15:23:23

FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged s...

arcutis-biotherapeutics-stock-a-deep-dive-into-analyst-perspectives-4-ratings
Arcutis Biotherapeutics Stock: A Deep Dive...
07/10/2024 12:00:16

needham-reiterates-buy-on-arcutis-biotherapeutics-maintains-18-price-target
Needham Reiterates Buy on Arcutis Biothera...
07/10/2024 10:26:05

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.

trading-halt-halt-status-updated-at-51500-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 5:15:...
07/09/2024 21:15:04

arcutis-biotherapeutics-says-fda-approved-snda-for-zoryve-roflumilast-cream-015-for-treatment-of-mild-to-moderate-atopic-dermatitis-in-adult-and-pediatric-patients-6-years-of-age-and-older
Arcutis Biotherapeutics Says FDA Approved ...
07/09/2024 20:55:25

ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch and has been...

trading-halt-halted-at-42538-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:25:38 p.m. ET - ...
07/09/2024 20:25:42

arcutis-provides-update-on-snda-for-roflumilast-cream-015-says-fda-has-indicated-that-they-are-working-to-finalize-the-action-letter-and-have-not-indicated-they-would-extend-the-pdufa-goal-date-of-july-7-2024
Arcutis Provides Update On sNDA for Roflum...
07/09/2024 12:33:20

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inno...

arcutis-biotherapeutics-announces-fda-approval-of-supplemental-new-drug-application-for-zoryve-roflumilast-cream-015-to-treat-mild-to-moderate-atopic-dermatitis-in-adults-and-children-6-and-older
Arcutis Biotherapeutics Announces FDA Appr...
07/08/2024 16:01:52

https://drugstorenews.com/fda-approves-arcutis-zoryve-treatment-atopic-dermatitis

intapp-servicenow-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Intapp, ServiceNow And Other Big Stocks Mo...
07/08/2024 12:22:50

vanda-pharmaceuticals-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Vanda Pharmaceuticals And Other Big Stocks...
06/20/2024 09:29:09

arcutis-presents-new-long-term-data-of-roflumilast-cream-015-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-adults-and-children-down-to-age-6-at-the-revolutionizing-alopecia-areata-vitiligo-and-eczema-conference
Arcutis Presents New Long-Term Data Of Rof...
06/10/2024 18:32:07

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through ...

arcutis-reports-multiple-abstracts-including-oral-presentation-at-the-revolutionizing-alopecia-areata-vitiligo-and-eczema-conference-from-june-8-10-2024
Arcutis Reports Multiple Abstracts, Includ...
06/05/2024 12:07:36

New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be...

why-bolt-biotherapeutics-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Bolt Biotherapeutics Shares Are Tradin...
05/15/2024 17:38:38

needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-18
Needham Maintains Buy on Arcutis Biotherap...
05/15/2024 15:51:18

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

nextracker-posts-upbeat-earnings-joins-mondaycom-nu-holdings-and-other-big-stocks-moving-higher-on-wednesday
NEXTracker Posts Upbeat Earnings, Joins mo...
05/15/2024 14:21:59

Core News & Articles
Market-Moving News for May 15th
05/15/2024 12:33:09

EDBL: 87% | Edible Garden shares are trading higher. The company reported Q1 financial results. MNDY: 22% | Monday.com shares ...

why-arcutis-biotherapeutics-shares-are-trading-higher-by-29-here-are-20-stocks-moving-premarket
Why Arcutis Biotherapeutics Shares Are Tra...
05/15/2024 12:14:56

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
05/15/2024 12:06:56

mizuho-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-18
Mizuho Maintains Buy on Arcutis Biotherape...
05/15/2024 11:09:02

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $17 to $18.

arcutis-biotherapeutics-stock-climbs-after-blockbuster-q1-results
Arcutis Biotherapeutics Stock Climbs After...
05/14/2024 21:11:26

Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)